Emergent BioSolutions (EBS) reported Q4 adjusted net income late Monday of $0.05 per diluted share, compared with a $0.77 loss a year earlier.
Three analysts polled by FactSet, on average, expected a $0.43 loss.
Revenue for the quarter ended Dec. 31 was $194.7 million, down from $276.6 million a year earlier.
Four analysts expected $249.5 million.
For Q1, the company is projecting $200 million to $240 million in revenue.
One analyst expects $279 million.
For 2025, the company is expecting $750 million to $850 million in revenue.
Three analysts are looking for $1.11 billion.
Shares of Emergent BioSolutions were down nearly 5% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。